Status | Study |
Recruiting |
Study Name: Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors Condition: Neurofibromatosis 2 Vestibular Schwannoma Date: 2017-03-08 Interventions: Drug: Selumetinib Continuous twice daily dosing; oral agent |
Recruiting |
Study Name: Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Condition: Vestibular Schwannoma Neurofibromatosis Type 2 Date: 2016-10-13 Interventions: Drug: Icotinib Method of drug administration:oral; Dosage: 125mg/m3/d; Course of treatment: 3 months;Tot |
Recruiting |
Study Name: AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas Condition: Neurofibromatosis 2 Meningioma Date: 2016-07-07 Interventions: Drug: AZD2014 |
Recruiting |
Study Name: Resiliency Training for Patients With NF2 Via Videoconferencing With Skype Condition: Neurofibromatosis 2 Date: 2016-06-21 Interventions: Behavioral: Stress Management Group 1 |
No longer available |
Study Name: Compassionate Use Arm - ABI541 ABI for 10 NF2 Patients Condition: Neurofibromatosis Type 2 Severe Profound Sensorineural Hearing Date: 2015-10-27 Interventions: Device: Nucleus Profile ABI541 Auditory Brainstem Implant |
Recruiting |
Study Name: Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas Condition: Intracranial Meningioma Recurrent Meningioma Date: 2015-08-11 Interventions: Drug: vismodegib Given PO |
Recruiting |
Study Name: Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations Condition: Solid Malignancy Solid Tumor Date: 2015-01-28 Interventions: Drug: Everolimus Other Names: RAD001 Afinitor Votubia |
Recruiting |
Study Name: Effect of Implant Position on Magnetic Resonance Image Distortion Condition: Neurofibromatosis Type 2 Date: 2014-09-18 Interventions: Device: MR imaging |
Recruiting |
Study Name: Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas Condition: Neurofibromatosis Type 2 Vestibular Schwannomas Date: 2014-04-29 Interventions: Drug: Axitinib Other Name: Inlyta |
Completed |
Study Name: Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Condition: Vestibular Schwannoma Neurofibromatosis Type 2 Date: 2014-03-26 Interventions: Drug: Endostatin Method of drug administration:continuous intravenous pumping; Dosage: 7.5mg/m2/d; Cours |